Kezar Life Sciences, Inc. Annual Report Summary

I’ve put together this guide to help you understand Kezar Life Sciences’ performance over the past year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do and how did they perform this year?

Kezar is a biotech company in the research phase. They do not currently sell any commercial products; instead, they focus on discovering treatments for autoimmune diseases and cancer. Their primary drug candidate is zetomipzomib. This year, the company shifted its strategy away from aggressive growth and is now exploring "strategic alternatives," which includes evaluating potential sales, mergers, or licensing agreements. This pivot follows the discontinuation of their PALIZADE clinical trial for lupus nephritis.

2. Financial performance

Because Kezar is not yet selling a product, they are not currently profitable. They reported a loss of approximately $105.8 million for fiscal year 2024. The company is funding its research operations through its existing cash reserves. As of mid-2025, the company’s total market value was approximately $33 million. To manage their resources, they implemented cost-cutting measures, including a 41% reduction in staff in late 2024 and the closure of their Australian branch.

3. Major wins and challenges

The company’s primary focus is managing its "cash runway"—the amount of time they can operate before needing additional capital. They currently hold approximately $109.5 million in cash and investments, which they project will sustain operations into 2027. To protect against a hostile takeover, the board has implemented a "poison pill" plan, which restricts any entity from acquiring more than 15% of the company without board approval.

4. Financial health

Kezar is currently operating in a survival-focused mode. They maintain their remaining capital in conservative assets, such as U.S. Treasury bills. They carry a loan from Oxford Finance, which provides operational liquidity but requires ongoing debt service payments as they work toward their clinical milestones. Their status as a "smaller reporting company" reflects their current size and the high-risk nature of their developmental pipeline.

5. Key risks

The business model is highly concentrated on the success of their clinical trials. If remaining studies, such as the PORTOLA study for autoimmune hepatitis, fail to yield positive results, the company has limited alternative revenue streams. Furthermore, because the company is small, they may need to raise additional capital by issuing new shares. This would dilute the ownership percentage of existing shareholders and could negatively impact the value of your investment.

6. Future outlook

The company is at a critical crossroads. Their future depends entirely on the success of their scientific research and their ability to secure a partnership or sale. Investors should monitor upcoming clinical trial results and any official announcements regarding their search for a strategic partner.

---

Note: This is a high-risk sector. As an investor, you are betting on the success of their science rather than their current sales. Please proceed with caution and consider whether this level of risk aligns with your personal investment strategy.